Vertex Pharmaceuticals secured a Buy rating from Leerink Partners analyst David Risinger. The firm’s newly approved pain ...

Not a moment too soon: a drug is on the market that is effective in treating pain but is not addictive. Its generic name is suzetrigine — sold under the name Journavx — and it took 25 years to develop ...

LTG-001, a selective inhibitor for treatment of acute pain, was granted Fast Track designation by the Food and Drug Administration (FDA).

In two randomized clinical trials evaluating pain control following abdominoplasty and bunionectomy, Journavx demonstrated ...

Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.